NVST

Analyst Note: NVST (Envista Holdings Corp)

Date: 2026-06-13 Current Price: $25.91

1. Structural Readiness

• Conservative Entry: Not yet defined (requires confirmed breakout above the coil resistance).
• Aggressive/Pre-Breakout Entry: Not actionable on setup alone; requires confirmation.
• Breakout Level: Not yet established (requires price to close above the coil resistance).
• Current Price: $25.91.
• Extension: Not applicable (price is within the coil range, not extended above entry).
• ATR Context: Current ATR is 3.4% (productive). This sits within the historical "sweet spot" (4–6% is ideal, but 3.4% indicates manageable volatility for sizing, well below the "extreme" >8% risk zone).

2. Thesis Layer

• Thesis Classification: TACTICAL / SETUP-LED.
• Macro Thesis: There is no named secular thesis attached to this specific setup at this date. The analysis must rely strictly on the quality of the technical structure (the forming coil) and the underlying business fundamentals reported as of May/June 2026. Do not invent a macro narrative; judge the name on its execution and setup readiness.

3. Business Overview

Envista Holdings Corp is a global dental solutions provider organized into two primary segments: Specialty Products & Technologies and Equipment & Consumables.

• Business Model: The company operates a "family of more than 30 trusted dental brands" (including Nobel Biocare, Ormco, DEXIS, and Kerr) focused on diagnosing, treating, and preventing dental ailments. The model is heavily weighted toward recurring revenue, with approximately 85% of 2025 sales derived from consumables, services, and spare parts.
• Segment Performance (as of Q1 2026):
• Specialty Products & Technologies: Generated $1,752.8 million in sales in 2025, growing 8.4% year-over-year. In Q1 2026, this segment saw double-digit growth in Ortho consumables and diagnostics, with implants growing mid-single digits (excluding China).
• Equipment & Consumables: Includes digital imaging (DEXIS), endodontics, and restorative materials. DEXIS maintains the largest installed base of imaging systems with roughly 275,000 connected devices.
• Growth Drivers:
• Clear Aligners: A major growth engine. As of April 3, 2026, remaining performance obligations were $171.3 million, with $130.8 million specifically tied to clear aligner treatment plans.
• Volume & Pricing: Q1 2026 sales increased 14.4% (core growth 8.4%), driven by a 7.1% increase in sales volume (largely from aligner timing) and a 1.3% increase in sales price.
• Capital Allocation: The Board recently authorized an incremental $300 million addition to the share repurchase program.
• Customer Concentration: The largest customer (Henry Schein) accounted for approximately 11% of sales in Q1 2026 and 12% in 2025.
• Macro/Regulatory Headwinds: Management noted a negative impact from 4 fewer billing days in Q4 2026 and exposure to U.S. trade policy actions (tariffs) affecting imports, particularly from China.

4. Archetype and Conviction

• Archetype: Growth Leader.
• *Fit:* The company demonstrates consistent double-digit growth in key segments (Ortho, DEXIS), a high-margin recurring revenue model (85% consumables), and active capital return ($300M buyback). The "digitization of dental practices" and "emerging market expansion" are cited by management as structural drivers.
• Valuation Context:
• Forward consensus EPS for FY1 is $1.43 and FY2 is $1.57.
• At a current price of $25.91, the stock trades at approximately 18.1x FY1 EPS and 16.5x FY2 EPS.
• Conviction Stack:
• Thesis Strength: Moderate (Tactical setup, no macro tailwind named).
• Evidence Quality: High. Recent earnings (May 2026) and filings (Feb 2026) provide granular data on segment growth, backlog ($171M), and capital allocation.
• Structural Quality: The "Forming" coil indicates a healthy consolidation phase. The 3.4% ATR suggests the stock is not in a high-volatility panic state.
• Rerating Potential: Dependent on the successful navigation of tariff headwinds and the realization of the $130M aligner backlog.

5. Invalidations, Strengtheners, and Gaps

• Strengtheners: A confirmed breakout above the coil resistance (price action) combined with management raising guidance for the "negative impact" of the 4 fewer billing days in Q4 2026 (i.e., showing resilience). Continued double-digit growth in Ortho consumables would further validate the growth leader archetype.
• Evidence Gaps:
• Breakout Level: The specific resistance level required for a confirmed breakout is not defined.
• Tariff Impact Quantification: While tariffs are mentioned as a headwind, the specific dollar impact on margins for 2026 is not quantified in the provided text.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key evidence: 9.5% core growth in Q1 2026; $300M incremental buyback authorization; $130.8M in clear aligner backlog; 85% of sales from recurring consumables/services. Key risks: 4 fewer billing days in Q4 2026 reducing revenue; U.S. trade tariffs on imports from China; customer concentration (Henry Schein at 11%); lack of named macro thesis. Sizing hint: Position size based on 3.4% ATR volatility; maintain standard risk parameters for a forming coil until breakout confirmation. Expected path: Management expects the dental market to remain resilient despite macro volatility; the company plans to invest further in Specialty Products & Technologies capacity in 2026. Expected horizon: 3 to 6 months for the forming coil to resolve into a confirmed breakout or invalidation.